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cense.Abstract Background: Pituitary tumors are a common form of endocrine neoplasia. However few
studies assessed the expression of the principal cyclin regulating checkpoint exit, cyclin D1. Cyclin
D1 expression in pituitary tumors and its possible relation to MIB-1 and p27/Kip1 labeling indices
(LIs) was explored.
Design: We studied a total of 199 pituitaries, including normal pituitaries (n= 7), pituitary adeno-
mas (n= 187), and pituitary carcinoma (n= 5). All tissues were tested as cores of archived tissue
microarrays that were immunostained for cyclin D1,MIB-1 and p27 using a standard technique. Tis-
sue cores were subjected to automated analysis to evaluate the staining LIs.
Results: No cyclin D1 positive cells in the normal anterior pituitary gland was found. Sparse nuclear
staining was noted in pituitary tumors. Higher expression of cyclin D1 was noted in pituitary carcino-
mas compared to adenomas (p< 0.001), in non-functioning adenomas compared to functioning ones
(p< 0.001) in macroadenomas versus microadenomas (p= 0.017) and in recurrent non recurrent
adenomas (p< 0.001). Cyclin D1 LI and MIB-1 LI were related among adenomas (p< 0.001) and
carcinomas (p= 0.041). p27 LI was neither related to pituitary adenoma recurrence nor invasion.
Conclusions: Expression of cyclin D1 in pituitary tumors is related to cell proliferation, recurrence,
and metastatic potential. Nuclear cyclin D1 expression is a good marker of aggressive behavior in
pituitary tumors.
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Pituitary neoplasms are relatively common tumors that exhibit
a wide range of hormonal activities and proliferative behaviors
[1,2]. These tumors are responsible for an estimated 10% of all
intra-cranial tumors [3]. Their classiﬁcation is a dynamic area
requiring continuous critical review due to advances in
molecular genetic techniques and new immunohistochemical
172 I.H. Hewedi et al.stains providing a clearer understanding of cell lineages and
pathogenetic mechanisms in adenohypophysial tumors [2].
The best predictive markers remain those that subclassify
adenomas accurately based on hormone content and cell struc-
ture. A silent corticotroph adenoma will recur more often and
more aggressively than a silent gonadotroph adenoma. How-
ever, the diagnosis of primary pituitary carcinoma remains
based solely on the identiﬁcation of distant metastasis. While
this facilitates the diagnostic approach to these tumors, it
seems inappropriate [2].
Pituitary tumors that can cause signiﬁcant morbidity due to
hormone hypersecretion, often invade the brain, causing blind-
ness and nerve palsies, require radiotherapy, and ultimately
cause death in some patients. The wide spectrum of biological
behavior that they display and the linkages or lack thereof be-
tween differentiated activity and cell proliferation makes pitu-
itary adenomas an ideal model for the study of mechanisms of
tumorigenesis [2].
The deregulation of genes involved in the control of the cell
cycle is one of the most common alterations in tumor growth;
cells with such a defect often have a growth advantage over
their neighbors. Progression through G1 to the S phase of
the cycle is mediated by the interplay between proteins control-
ling pRb phosphorylation. Under mitogenic stimulation,
the cyclin D1 protein binds to cyclin-dependent kinase 4
(CDK-4), which is subsequently activated and phosphorylates
pRb. In a hyperphosphorylated form, pRb is inactivated, and
the cells are released from G1 arrest. In contrast, under
growth-inhibitory conditions, kinase inhibitors bind competi-
tively to CDK 4, effectively keeping the cell in G1 and thus
preventing cell division [4–6]. It has been demonstrated that
cyclin D1 may play a role in sequestering p27 in the cell cyto-
plasm. This suggested that prevention of the functional nuclear
localization of p27 protein could also potentially play a role in
cell cycle dysregulation [7].
The cyclin D1 gene (CCND1), located at 11q13, is one of the
most frequently ampliﬁed genes observed in human tumors,
with ampliﬁcation of CCND1 frequently leading to cyclin D1
protein over expression [4–6]. In head and neck cancers [8,9], cy-
clin D1 ampliﬁcation and over expression are associated with a
poor prognosis, whereas in other cancers such as breast [10],
bladder [11], and non-small cell lung cancers [12], over expres-
sion of cyclin D1 correlates with good prognosis.
Although cyclin D1 has been studied extensively in a num-
ber of human malignancies, including breast, lung, and blad-
der cancers, and lymphomas, there are currently only limited
data on cyclin D expression in pituitary tumors [13,14].
The aim of the current study is to investigate: 1 – the pos-
sible role of cyclin D1 over-expression in pituitary tumors
compared to normal pituitary gland, 2 – the possibility of cat-
egorizing different pituitary tumors according to their cyclin
D1 expression in addition to immunophenotype and clinical
behavior, and 3 – the relationship between cyclin D1 and both
MIB-1 or p27 labeling indices.Material and methods
Tissue samples
This study included formalin-ﬁxed parafﬁn-embedded tissues
from 192 pituitary tumors, in addition to 7 normal anteriorpituitary tissues. All cases were operated upon at Saint Mary’s
Hospital; one of the Mayo hospitals in Rochester–MN–USA;
between 1982 and 2002 through transsphenoidal approach.
The study was approved by both the Biospecimens Sub-
committee of the Mayo Rochester Research Committee and
the Institutional Review Board (IRB).
(I) Pituitary adenomas studied (Total n= 187) included 34
prolactin (PRL) producing adenomas, 29 growth hormone
(GH) producing adenomas, 20 adrenocorticotropic hormone
(ACTH) producing adenomas, 2 thyroid stimulating hormone
(TSH) producing adenomas, 44 gonadotroph (LH/FSH) ade-
nomas, and 58 null cell adenomas. All had previously been
characterized by immunostaining with pituitary antibodies.
The GH adenomas group included plurihormonal GH adeno-
mas and adenomas producing both GH and PRL but not acid-
ophil stem cell adenomas.
Tumors producing GH and PRL were all endocrinological-
ly functioning at presentation, while eight ACTH producing
tumors were non-functional ‘‘silent’’. The remaining function-
ing ACTH producing tumors presented with either Cushing
disease (n= 10) or Nelson’s syndrome (n= 2).
The designation of the adenomas as microadenomas vs.
macroadenomas and non-invasive vs. invasive was assigned
upon revision of both image and surgery reports for each sin-
gle case. All the adenomas studied were retrieved as primary
excisions. Their post-operative two years follow-up revealed
recurrence of only 16 cases, which we designate as recurrent
adenomas.
(II) Pituitary carcinomas (Total n= 5) were previously
characterized by immunostaining and included three PRL,
one ACTH, and one LH/FSH carcinomas. Carcinomas were
very rare and deﬁned by the presence of metastatic disease.
(III) Non-tumorous anterior pituitary tissue samples (n= 7),
surgically removed in conjunction with small microadenomas
through transsphenoidal approach, were also studied as a con-
trol group. The number of the control group was few as the
normal anterior pituitary tissue was difﬁcult to be obtained.
For the present immunohistochemical study, we used tissue
microarrays (TMA) that were formerly created as described by
Kononen et al. [15] consisting of three cores of each specimen
interspersed with normal liver tissues.
Immunohistochemistry
The original tumors – both adenomas (n= 187) and carcino-
mas (n= 5) used for construction of the tissue microarrays
have been previously subjected to the seven pituitary battery
antibodies (Table 1). Antigen unmasking procedure with pro-
tease II was performed only for b-FSH staining while no pre-
treatment was required for the remaining of the pituitary
battery hormones. Staining was then carried out by Ventana
ES (320) automated immunohistochemical stainer using
AEC-detection kit (Ventana Medical Systems Inc. ‘‘VMS’’–
Tucson–AZ–USA).
The resultant TMA slides have been presented to immuno-
staining applying antibodies for cyclin D1, p27 and Ki-67 (Ta-
ble 1). Antigen unmasking procedure was carried out using
citrate buffer pH6 for cyclin D1 and 1 mM EDTA pH 8 for
both p27and Ki-67 staining. Staining was performed by
DAKO EnVision Autostainer (DakoCytomation–Carpente-
ria–CA–USA) with diaminobenzidine (DAB) for color
development.
Table 1 Technical characteristics of immunohistochemical methodology.
Protein Origin Clone Dilution
PRL Vector Labs, Burlingame, CA, USA INN-hPRL-3 1: 75
GH Vector Labs, Burlingame, CA, USA Polyclonal 1: 250
ACTH Vector Labs, Burlingame, CA, USA Clone 56 1: 300
b-FSH Vector Labs, Burlingame CA, USA INN-h FSH-60 1: 2500
TSH Vector Labs, Burlingame, CA, USA QB2/6 1: 100
b-LH DakoCytomation, Carpenteria, CA, USA C93 1:75
-SU Chemical Reagent Lab, Mayo Foundation, MN, USA Polyclonal 1: 50,000
Cyclin D1 Thermo Fisher Scientiﬁc, Fremont, CA, USA Polyclonal Ready-to-use
P27 DakoCytomation, Carpenteria, CA, USA SX53G8 1: 1000
Ki67(MIB-1) DakoCytomation, Carpenteria, CA, USA Ki-S5 1:100
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man pituitary for pituitary battery antibodies, breast carci-
noma for cyclin D1, and tonsillar tissue for both p27 and
Ki-67). Slides with ‘no primary antibody’ served as negative
control.
Quantitation
The TMA slides were scanned using the BLISS System–Slide
scanner (Bacus Laboratories Inc.–Lombard–IL–USA).Table 2 Clinical characteristics by pituitary tumor type.
Tumor type Clinical characteristics
n Sex (% male) Age (mean) Size
Macro-n (
Pituitary adenomas
All Adenomas 187 63.1 49.1 165 (88.2)
PRL 34 52.9 40.1 25 (73.5)
GH 29 65.5 42.2 26 (89.7)
ACTH
Cushing 10 30 50.9 2 (20)
ACTH Nelson 2 0 52 2 (100)
Silent ACTH 8 50 46.2 7 (87.5)
TSH 2 100 46.5 2 (100)
LH/FSH 44 75 60.5 43(97.7)
Null 58 67.2 54.7 58 (100)
Pituitary carcinomas
Carcinomas 5 20 54.5 5 (100)
(% +): percent of invasive or recurrent cases.
Table 3 Cyclin D1 expression in different pituitary tumor types.
Tumor type Protein expression n of cases (%)
0 1+ [LI 0.4–<0.6] 2
All adenomas 103 (55.1) 21 (11.2) 2
PRL 20 (58.8) 4 (11.8) 8
GH 15 (51.7) 5 (17.2) 9
ACTH 11 (55) 4 (20) 5
TSH 1 (50) 0 (0) 1
LH/FSH 32 (72.2) 8 (18.2) 4
Null 24 (41.1) 0 (0) 0
Carcinomas 0 (0) 0 (0) 0Images were digitally captured at 20· magniﬁcation using a
12-tile matrix of images per core for a ﬁnal resolution of
1920 · 2256 pixels per TMA core. Quantiﬁcation of the la-
beled cells was performed using computer assisted TMA
score software (Bacus Laboratories Inc.). Assessment of the
cyclin D1, MIB-1, and p27 labeling indices was subsequently
calculated as the percentage of cells showing deﬁnite positive
nuclear staining with examination of at least 1000 cells in the
three different cores per tumor specimen according to Turner
et al. [14].Invasion n (% +) Recurrence n (%+)
%) Micro-n (%)
22 (11.8) 115 (61.5) 16 (8.6)
9 (26.5) 22 (64.7) 3
3(10.3) 15 (51.7) 1
8 (80) 2 (20) 1(10)
0 (0) 2 (100) 0 (0)
1 (12.5) 4 (50) 1 (12.5)
0 (0) 1 (50) 0 (0)
1(2.3) 28 (63.6) 0 (0)
0 (0) 41 (70.7) 10 (17.2)
0 (0) 5 (100) –
+ [LI 0.6–<1.5] 3+ [1.5–<1.8] 4+ [LI 1.8–2.5]
7 (14.4) 24 (12.8) 12 (6.4)
(23.5) 1(2.9) 1(2.9)
(31) 0 (0) 0 (0)
(25) 0 (0) 0 (0)
(50) 0 (0) 0 (0)
(9.1) 0 (0) 0 (0)
(0) 23 (39.7) 11 (19)
(0) 1 (20) 4 (80)
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Predictive Analytics Software (PASW) statistical software
package (V. 18.0, IBM Corp., USA, 2010) was used for data
analysis. Data were categorized according to their distribution
and expressed as number (n) and percentage (%) for each
group or subgroup. All tests were two-sided and p-values less
than 0.05 were considered statistically signiﬁcant. Any com-
parison of two discrete variables was made with chi-square
test. Ranked Sperman correlation test was used to study the
possible association between two variables among each group
for non-parametric data. Diagnostic validity tests were per-
formed and Receiver Operating Characteristic (ROC) curves
were constructed to obtain the most sensitive and speciﬁc
cut-off for cyclin D1, MIB-1 and p27 LIs in discriminating be-
tween pituitary adenomas and carcinomas. For statistical pur-
pose, cyclin D1 LIs in pituitary tumors were classiﬁed into ﬁve
groups; 0 (LI 0%), 1+ (LI 0.4–<0.6), 2+ (LI 0.6–<1.5%),
3+ (1.5–<1.8%), and 4+ (LI 1.8–2.5%).Results
The clinical characteristics for the studied pituitary tumors are
summarized in Table 2.
Cyclin D1 expression
All the studied tissue samples showed no evidence of cytoplas-
mic staining for cyclin D1. Overall, positive nuclear expression
was seen in 84 of 187 (44.9%) pituitary adenomas, were graded
either 2+ in 27 cases (14.4%) or 3+ in 24 cases (12.4%). All
the ﬁve studied pituitary carcinoma cases revealed positive nu-
clear staining for cyclin D1 and four (80%) of them were
graded as 4+. Cyclin D1 LI for all the positive cases of pitu-
itary tumors ranged between 0.4% and 2.5%. In contrast, in
the normal anterior pituitary gland, there were no cyclin D1
positive cells (Table 3 and Fig. 1). On comparing adenomas
to carcinomas, a highly signiﬁcant difference was revealed
(p< 0.001), while no statistical signiﬁcant difference was ob-
tained on comparing adenomas to normal pituitaries
(p= 0.236).Figure 1 Cyclin D1 expression in human pituitary tissues. (a)
Normal anterior pituitary tissue with negative staining for cyclin
D1 [X 200]. (b) Null cell adenoma showing scattered cells
expressing cyclin D1 [X 400]. (c) PRL cell carcinoma with 4+
cyclin D1 expression [X 400].Relationship of cyclin D1 LI to tumor type and clinical
characteristics
The carcinoma group clearly demonstrated higher cyclin D1
expression compared to adenoma group (Pearson chi-square,
p< 0.001). Among the adenoma group, null cell adenomas
showed signiﬁcantly higher cyclin D1 expression compared
to all the other adenoma subgroups; PRL (p< 0.001), GH
(p< 0.001), ACTH (p< 0.001), TSH (p< 0.001), and LH/
FSH (p< 0.001). On comparing adenomas which showed
recurrence on follow up to those who did not have an evi-
dence of recurrence, a signiﬁcant higher cyclin D1 expression
was noted in the former subgroup (p< 0.001). Also, non
functioning adenomas [LH/FSH and Null cell adenomas]
showed signiﬁcantly higher cyclin D1 expression upon com-
parison with the endocrinologically functioning ones [PRL,
GH, Cushing and Nelson ACTH cases] (p< 0.001). On
comparing silent ACTH adenomas to the functioning ones(Cushing and Nelson adenomas), no signiﬁcant difference
was observed regarding cyclin D1 expression (p= 0.893).
There is a signiﬁcant relationship was noted between Cyclin
D1 expression and adenoma size (p= 0.017), while no sig-
niﬁcant difference between Cyclin D1 expression and ade-
noma invasion (p= 0.067) (Table 4).
Table 4 Cyclin D1 expression by pituitary adenomas clinical characteristics.
Clinical characteristics Protein expression n of cases (%) Statistical analysis*
(signiﬁcance)
0 1+ [LI 0.4–<0.6] 2+ [LI 0.6–<1.5] 3+ [1.5–<1.8] 4+ [LI 1.8–2.5]
Recurrence
Recurrent 4 (25) 2 (12.5) 0 (0) 6 (37.5) 4 (25) p< 0.001
Non-recurrent 99 (57.9) 19 (11.1) 27 (15.8) 18 (10.5) 8 (4.7) (H.S.)
Functional status
Functioning 42 (56) 11 (14.7) 20 (26.7) 1 (1.3) 1 (1.3) p< 0.001
Non-functioning 56 (54.9) 8 (7.8) 4 (3.9) 23 (22.5) 11 (10.8) (H.S.)
Size
Macroadenomas 88 (53.3) 20 (12.1) 21 (12.7) 24 (14.5) 12 (7.3) p= 0.017
Microadenomas 15 (68.2) 1 (4.5) 6 (27.3) 0 (0) 0 (0) (S.)
Invasion
Invasive 56 (48.7) 12 (10.4) 19 (16.5) 17 (14.8) 11 (9.6) p= 0.067
Non-invasive 47 (65.3) 9 (12.5) 8 (11.1) 7 (9.7) 1 (1.4) (N.S.)
* Pearson chi-square test. H.S.: highly signiﬁcant; S.: signiﬁcant; N.S.: non-signiﬁcant.
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The normal pituitaries studied showed nil to trivial MIB-1
expression with LI ranged between 0% and 0.04%. The
median MIB-1 LI among studied adenomas was 0.37%
and ranged between 0% and 9.76%, while the ﬁve studied
carcinomas showed median MIB-1 LI of 2.47% and ranged
between 0.6% and 7.5%. Regarding p27 expression, a wide
range of LI was noted among normal pituitaries (median
0.77; range 0.02–21. 39), adenomas (median 2.95; range
0.01–82.97), and carcinomas (median 1.76; range 0.54–3.39)
(Figs. 2 and 3).
Relationship between cyclin D1 and MIB-1 LIs
A signiﬁcant positive relationship was noted between cyclin D1
and MIB-1 labeling indices among adenomas (r= 0.619,
p< 0.001) and carcinomas (r= 0.894, p= 0.041). This
positive relationship between cyclinD1 andMIB-1LISwas con-
sistently noted among all the studied adenoma subgroups di-
vided according to immunophenotyping [PRL (r= 0.879,
p< 0.001), GH (r= 0.849, p< 0.001), ACTH (r= 0.854,
p< 0.001), LH/FSH (r= 0.781, p< 0.001), and Null
(r= 0.895, p < 0.001)]. Also, this signiﬁcant relation was
observed upon dividing adenomas according to size [macro-
adenomas (r= 0.663, p < 0.001), and micro-adenomas
(r= 0.612, p= 0.002)], functional status [functioning
(r= 0.675, p < 0.001), and non functioning (r= 0.79,
p< 0.001)], Invasive status [invasive (r= 0.629, p < 0.001)
and non invasive (r= 0.601, p< 0.001)], and ﬁnally according
to recurrence [recurrent (r= 0.625, p= 0.01) and non recurrent
(r= 0.615, p< 0.001)].
Relationship between cyclin D1 and p27 LIs
No signiﬁcant relationship was noted between cyclin D1 and
p27 LIs among either adenomas (r= 0.059, p= 0.424) or
carcinomas (r= 0.112, p= 0.858).Discriminating cut-off value for cyclin D1, and MIB-1 labeling
indices between adenomas and carcinomas
Although the number of studied pituitary carcinoma cases is
only ﬁve owing to the extreme rarity of the documented cases,
an attempt to mark out cut-off values to discriminate carcino-
mas from adenomas with reasonable speciﬁcity and sensitivity
was conducted for the studied markers namely cyclin D1. The
ROC curves created for this purpose are shown in Fig. 4. The
best cut-off cyclin D1 LI detected was 1.7% at which the sen-
sitivity (Sn) was = 80; the speciﬁcity (Sp) was = 93.6; the neg-
ative predictive value (P) was = 99.4, the positive predictive
value (P+) was = 25 and the efﬁcacy was = 93.23. When
MIB-1 LI was investigated, a cut-off value of 0.59 was advo-
cated but with overall efﬁcacy of only 70.31 (Sp = 69.52,
Sn = 100, P= 100, P+= 8.06). p27 LI was totally unreli-
able in this tedious attempt to segregate carcinomas from ade-
nomas. Multi-ROC curve analysis reveal that combined best
cut-off for cyclin D1 and MIB-1 LIS at 1.7 and 0.55 respec-
tively offered slightly higher accuracy compared to cyclin D1
only (Sn = 100, Sp = 94.7, P= 100, P+= 33.3, and
efﬁcacy = 94.8).Discussion
This study provides further evidence that deregulation of genes
involved in the G1-S phase transition is important in pituitary
tumorigenesis. Cyclin D1 protein was frequently over ex-
pressed in human pituitary tumors compared to the normal
pituitary, where no staining was observed in the latter.
The majority of pituitary tumors showed either negative
immunostaining for cyclin D1 or its presence in less than
10% of the cells. It should also be noted that all positive pitu-
itary tumors showed staining conﬁned to the nucleus. This is in
agreement with previous studies [16,17]. However, this dis-
agrees with another study group [18] who found cytoplasmic
staining for cyclin D1 in the U-2-OS pituitary cell line. They
mentioned a differential solubility of cyclin D1 protein to ex-
Figure 2 MIB-1 expression in normal anterior pituitary tissue
(a), TSH adenoma (b), and PRL cell carcinoma (c) [All X 400].
Figure 3 p27 Expression in LH/FSH adenoma (a), and LH/FSH
carcinoma (b) [All X 400].
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importance of cytoplasmic cyclin D1 expression in tumors
showing this phenomenon is not understood.
We were able to demonstrate that pituitary tumors as a
group had a large number of samples with signiﬁcant cyclin
D1 positivity compared with normal pituitary. Overall, posi-
tive nuclear expression was seen in 84 of 187 (44.9%) pituitary
adenomas and LI for all the positive cases of pituitary tumors
were mostly graded either 2+ or 3+. The cyclin D1 positive
expression occurred with sub-group analysis and principallydue to the non-functioning tumors mainly null cell adenomas;
indicating that the inappropriate expression of cyclin D1 may
play a more important role in nonfunctional pituitary tumors
than in functioning tumors. This is in agreement with other
studies which demonstrated that the expression of different
genes or proteins is altered during tumorigenesis of different
pituitary subtypes [16,19,20] with some evidence of cyclin D1
allelic imbalance in one fourth of the tumor samples analyzed
by Hibberts and colleagues [13].
Non-functioning pituitary tumors are generally larger than
other types [21,16], the current study could establish a signiﬁ-
cant relationship between cyclin D1 expression and adenoma
size. Therefore the noted difference between null cell adenomas
and other adenoma types is likely to be related to the immuno-
phenotype as well as the adenoma size. These results are in
accordance with that of Turner et al. [14].
Ampliﬁcation of cyclin D1 gene (CCND1) is more common
in invasive than in noninvasive pituitary adenomas [22]. In our
study, the expression of cyclin D1 was noted in 51.3% of inva-
sive adenomas compared to only 34.7% of non invasive ones
but this difference did not reach statistical signiﬁcance. Pitui-
tary carcinomas showed a signiﬁcantly higher expression of cy-
clin D1 compared to adenomas. However, Jordan and his
group in 2000 [16], found that pituitary carcinomas did not ap-
pear to differ from the more benign tumors. They found that
combining the groups according to tumor grade (adenoma,
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Figure 4 ROC curve analysis showing the diagnostic perfor-
mance of Ki67, p27 and cyc-D1 for discriminating patients with
carcinoma from those with adenoma.
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group effect.
Previous studies have also shown that in colorectal [23],
breast [24] and lung tumors [25], cyclinD1 expression is an
early event in tumorigenesis and is maintained in more ad-
vanced stages of the disease. Two studies suggested that over
expression of cyclin D1 is an early event in tumorigenesis
responsible for initial clonal expansion of the tumor, whilst
subsequent loss of pRb expression results in complete
disruption of this G1 check point, thereby giving an additional
growth advantage to tumor cells [26,27].
Previous studies, especially on the cell cycle regulation,
have shown that deregulation of the cyclin D/cyclin-dependent
kinases (CDK)/CDK inhibitor /pRb pathway in the G1/S
phase may represent an obligatory step in pituitary tumorigen-
esis [28,29]. However in addition to ampliﬁcation, inappropri-
ate cyclin D1 expression may be due to another principal
mechanism which is cytogenic inversion as described in
parathyroid tumors [30]. This is further highlighted in the
few reports on the cyclin D1 overexpression and its genetic
alteration in pituitary adenomas suggesting that the overex-
pression of cyclin D1 occurs early and late in pituitary tumor-
igenesis and this is not necessarily associated with cyclin D1
gene allelic imbalance [13,16,31].
In our study, a signiﬁcant positive correlation was noted
between cyclin D1 and tumor recurrence, which was previ-
ously described in squamous cell carcinoma of the headand neck [9]. Conversely, cyclin D1 over expression was
associated with a lower rate and/or interval to recurrence
in breast, bladder and non-small lung cancer. The conﬂicting
data regarding the correlation between cyclin D1 over
expression and tumor recurrence support that the inﬂuence
of gene polymorphism is perhaps dependent on tumor type
[17].
Theoretically, proliferation markers should help in differ-
entiating aggressive or rapidly growing tumors from those
with slower growth, as cellular atypia is not helpful for iden-
tifying aggressive adenomas of the pituitary [32]. In our
study; a signiﬁcant positive correlation was noted between
cyclin D1 and MIB-1 LIs among adenomas and carcinomas.
This positive correlation was consistently noted among all
the studied adenoma subgroups. This positive correlation
suggests that a constant ratio of cells that have entered the
cell cycle continue to proliferate. Therefore the signal to cy-
clin D expression is strong enough to override the G1/S
checkpoint where cells then become ‘committed’ to the cell
cycle. This conﬁrms the hypothesis that cyclin over-expres-
sion is secondary to an increased number of cells entering
the cell cycle and therefore increased proliferation rather
than cell cycle deregulation [16]. These results are in
agreement with studies showing a correlation between
cyclins expression, cell proliferation and tumor progression
[14,33,34].
Both cyclin D1 and MIB-1 but not p27 LIs were reliable
predictors of carcinoma. We displayed that combined cyclin
D1 LI higher than 1.7% and MIB-1 LI higher than 0.55%
were capable of predicting carcinoma among studied pituitary
tumors with overall efﬁcacy of 94.8% though with a low (33%)
predictive value of positive test. This means that only one third
of the cases that have combined cyclin D1 and MIB-1 LIs
above 1.7% and 0.55%; respectively are truly carcinomas.
These cut off levels were excellent in excluding a given tumor
from the carcinoma group with zero false negative prediction.
In other words, a tumor having combined cyclin D1 and MIB-
1 LIs less than 1.7% and 0.55% respectively are in this series
exclusively adenomas.
Some groups have investigated p27 in pituitary tumors
[35–37]. In the current study, we failed to demonstrate a signif-
icant inverse correlation between cyclin D1 and p27 LIs. No
available studies, to date, have investigated the parallel expres-
sion of both markers in pituitary tumors, while a previous
study demonstrated that over expression of cyclin D1 and loss
of p27Kip1 was associated with carcinomas of thyroid gland
[35,38].
Given the relevance of cell cycle regulators in the correct
function of stem cells [39–41]; it is attempting to speculate
on the relevance of the cell cycle in pituitary stem cell self-
renewal and its implication in pituitary tumors. The
observed deregulation of the cell cycle in pituitary has
important consequences in the treatment of these tumors.
Several small molecular CDK inhibitors are now being
evaluated for cancer therapy in many different tumor types
[42,43]. Newer techniques including DNA and microRNA
microarrays will undoubtedly provide new candidates
important to the development and progression of pituitary
tumors. In this context, our results recommend cyclin D1
as a novel marker that deserve more studies among pitui-
tary tumors to elucidate its possible rule and perhaps its
further therapeutic implication.
178 I.H. Hewedi et al.Conclusion
Cyclin D1 is promising in predicting the clinical behavior of
pituitary tumors as regards adenoma recurrence and perhaps
carcinoma development. Whether cyclin D1 expression is a
primary event in pituitary tumor initiation and progression
or is secondary to other tumorigenic factors is unclear and re-
quires further investigation.References
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